Herantis Pharma Oyj (HE:HRTIS) is focused on the development of innovative regenerative medicines targeting unmet needs. Its two lead assets are cerebral dopamine neurotrophic factor (CDNF), a potential disease-modifying treatment for Parkinson’s disease (PD), and Lymfactin, the only gene therapy in development for breast cancer-related associated (BCAL) secondary lymphedema. The underlying science for both is novel and positive efficacy/safety data from ongoing proof-of-concept clinical trials expected in 2019–20 would serve as validation of the research efforts and additionally could crystallise value through partnering opportunities for these unique assets. We value Herantis Pharma at €9.3/share.
Neuroprotective CDNF for PD
As the second most common neurodegenerative disease in the world (c 10 million patients) and no treatment options that slow disease progression, PD is a significant problem for healthcare providers. The standard of care typically consists of daily L-DOPA treatment; however, it only improves motor symptoms over a limited time (three to five years). Herantis is developing CDNF, a neurotrophic factor that is believed to promote neurone survival and could potentially have an effect on motor and non-motor symptoms, in addition to potentially slowing down disease progression. It is in a Phase I/II trial and initial data are expected in H219.
To read the entire report Please click on the pdf File Below: